Personal Genome Diagnostics (PGDx) has partnered with Japan-based Eisai to develop a liquid biopsy biomarker discovery tool.

Oxford Nanopore Technologies said recently it has raised a total of ￡109.5 million ($144.4 million) between new capital investments and the sale of secondary shares.

Illumina and Pacific Biosciences announced recently after the close of the market that they have "mutually agreed" to terminate their merger agreement.

Diagnostics firm OncoCyte said recently that it has entered into definitive agreements with Pura Vida Investments, a healthcare focused registered investment advisor, and one other unnamed institutional investor......

DiaSorin Molecular has received US Food and Drug Administration clearance for its Simplexa VZV Swab Direct assay to detect varicella-zoster virus (VZV) DNA from cutaneous and mucocutaneous swab specimens, the firm announced recently.

LifeVault Bio, a consumer-facing company offering personal biobanking services under the name GoodCell, said recently that it has closed on $5.6 million in financing. That total includes $2.6 million in investments and a $3 million convertible note.

Grail has raised $125 million out of a planned $250 million equity financing offering, according to a recently filed Form D notice with the US Securities and Exchange Commission.

IncellDx said recently that that it has signed an agreement with Singapore-based Biolidics to distribute its IncellDx bioINK PD-L1 CTC Core Kit.

Biotia, a startup providing DNA sequencing-based microbial surveillance services and infectious disease diagnostic tests for hospitals, said recently that it has closed a $2.4 million seed financing round.

Invitae recently announced a partnership with BioMarin Pharmaceuticals on a program to expand access to genetic testing for skeletal dysplasias.

Twist Bioscience reported after the close of the market recently that revenues for its fiscal fourth quarter 2019 rose 87 percent year over year.

Cancer drug developer Oncology Pharma said recently that it has signed a letter of intent to acquire at least 50 percent of molecular genomics firm Diagnomics.

Prescient Medicine said this week that it has partnered with Dutch medical research institute Erasmus MC to evaluate its opioid addiction risk technology in a clinical study in the Netherlands.

Horizon Discovery and Mammoth Biosciences announced recently that they will collaborate to develop new CRISPR tools, with the aim of generating new engineered cell lines for the biopharmaceutical industry.

Healthcare artificial intelligence firm Tempus announced earlier this week the acquisition of Akesogen, the owner of a commercial laboratory and provider of genomics and clinical trial precision medicine services.